Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Anti-Glycoconjugate Antibody-Mediated Demyelinating Neuropathy
NCT00050245Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Nov 2002
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in anti-myelin-associated glycoprotein peripheral neuropathy, sponsored by National Institute of Neurological Disorders and Stroke. Started Nov 2002; status: completed.
02
Drugs
rituximab
03
Conditions
anti-myelin-associated glycoprotein peripheral neuropathy
Beyond the preview
Go deeper on NCT00050245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050245.